Loading
A phase 3 trial testing HS-20089 in ovarian cancer, now recruiting.
HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer is a phase 3 interventional study registered as NCT06855069, led by Hansoh BioMedical R&D, and recruiting on the registry. Official title: A Multi-centre, Randomised, Open-label, Controlled, Phase III Clinical Study Evaluating HS-20089 vs. Investigator's Choice of Chemotherapy in the Treatment of Platinum-resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer. Planned enrolment is 468 participants (estimated). The study started in 2025-03-13 and primary completion is expected in 2027-03-07. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares HS-20089, Hansoh Pharmaceutical, Ovarian cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/